Division of Vascular Surgery, St. Michael's Hospital, Toronto, ON, M5B 1W8, Canada.
Department of Surgery, Hamilton General Hospital, Hamilton, Canada.
Sci Rep. 2021 May 26;11(1):11061. doi: 10.1038/s41598-021-90395-0.
Plasma levels of fatty acid binding protein 3 (pFABP3) are elevated in patients with peripheral artery disease (PAD). Since the kidney filters FABP3 from circulation, we investigated whether urinary fatty acid binding protein 3 (uFABP3) is associated with PAD, and also explored its potential as a diagnostic biomarker for this disease state. A total of 130 patients were recruited from outpatient clinics at St. Michael's Hospital, comprising of 65 patients with PAD and 65 patients without PAD (non-PAD). Levels of uFABP3 normalized for urine creatinine (uFABP3/uCr) were 1.7-folds higher in patients with PAD [median (IQR) 4.41 (2.79-8.08)] compared with non-PAD controls [median (IQR) 2.49 (1.78-3.12), p-value = 0.001]. Subgroup analysis demonstrated no significant effect of cardiovascular risk factors (age, sex, hypertension, hypercholesteremia, diabetes and smoking) on uFABP3/uCr in both PAD and non-PAD patients. Spearmen correlation studies demonstrated a significant negative correlation between uFABP3/uCr and ABI (ρ = - 0.436; p-value = 0.001). Regression analysis demonstrated that uFABP3/Cr levels were associated with PAD independently of age, sex, hypercholesterolemia, smoking, prior history of coronary arterial disease and Estimated Glomerular Filtration rate (eGFR) [odds ratio: 2.34 (95% confidence interval: 1.47-3.75) p-value < 0.001]. Lastly, receiver operator curve (ROC) analysis demonstrated unadjusted area under the curve (AUC) for uFABP3/Cr of 0.79, which improved to 0.86 after adjusting for eGFR, age, hypercholesteremia, smoking and diabetes. In conclusion, our results demonstrate a strong association between uFABP3/Cr and PAD and suggest the potential of uFABP3/Cr in identifying patients with PAD.
血液脂肪酸结合蛋白 3 (pFABP3)水平在周围动脉疾病(PAD)患者中升高。由于肾脏从循环中过滤 FABP3,因此我们研究了尿脂肪酸结合蛋白 3(uFABP3)是否与 PAD 相关,并且还探索了其作为该疾病状态的诊断生物标志物的潜力。总共从圣迈克尔医院的门诊诊所招募了 130 名患者,其中包括 65 名 PAD 患者和 65 名非 PAD(非 PAD)患者。与非 PAD 对照组相比,pFABP3 [中位数(IQR)4.41(2.79-8.08)]患者的 uFABP3 /尿肌酐标准化(uFABP3 / uCr)水平高 1.7 倍[中位数(IQR)2.49(1.78-3.12),p 值= 0.001]。亚组分析表明,心血管危险因素(年龄,性别,高血压,高胆固醇血症,糖尿病和吸烟)对 PAD 和非 PAD 患者的 uFABP3 / uCr 没有显著影响。Spearmen 相关性研究表明,uFABP3 / uCr 与 ABI 之间存在显著负相关(ρ=-0.436;p 值=0.001)。回归分析表明,uFABP3 / Cr 水平与 PAD 相关,与年龄,性别,高胆固醇血症,吸烟,既往冠状动脉疾病和估计肾小球滤过率(eGFR)无关[优势比:2.34(95%置信区间:1.47-3.75),p 值<0.001]。最后,接受者操作特征曲线(ROC)分析显示,未经调整的 uFABP3 / Cr 曲线下面积(AUC)为 0.79,调整 eGFR,年龄,高胆固醇血症,吸烟和糖尿病后,AUC 提高至 0.86。总之,我们的结果表明 uFABP3 / Cr 与 PAD 之间存在很强的关联,并提示 uFABP3 / Cr 有潜力用于识别 PAD 患者。